[{"orgOrder":0,"company":"Endurance Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"T-168","moa":"PGC-1-alpha\/TFEB","graph1":"Neurology","graph2":"Phase II","graph3":"Endurance Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Endurance Bio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Endurance Bio \/ Inapplicable"}]
Find Clinical Drug Pipeline Developments & Deals for T-168
Details :
T-168 is an oral small molecule works by upregulating PGC-1α and TFEB to restore mitochondrial and lysosomal function, key processes implicated in the pathophysiology of Parkinson's.